Bayer Schering Pharma Ag

Schering Aktiengesellschaft

Schring Aktiengesellschaft

Andreas Reichel

Jens Hoffmann

Rolf Bohlmann

Arwed Cleve

Volker Schulze

Dieter Zopf

Rolf Jautelat

Orlin Petrov

Rosemarie Lichtner

Nikolaus Heinrich

Karsten Parczyk

Jorg Kroll

Andreas Huth

Martin Haberey

Karl-Heinz Thierauch

Stuart Ince

Martin Krueger

Holger Hess-Stumpp

Christoph Huwe

Helmut Morack

The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

This invention relates to anti-androgenic N-[&#x3c9;-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.

Anti-androgenic pyrrolidines with tumor-inhibiting action

The invention relates to 17&#x3b1;-alkyl-17&#x3b2;-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17&#x3b2;-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17&#x3b1;-alkyl-17&#x3b2;-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17&#x3b1;-alkyl-17&#x3b2;-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.

17&#x3b1;-alkyl-17&#x3b2;-oxy-estratrienes and intermediate products for their production, use of the 17&#x3b1;-alkyl-17&#x3b2;-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations

17&#x3b1;-ALKYL-17&#x3b2;-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17&#x3b1;-ALKYL-17&#x3b2;-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS

This invention relates to new piperazine derivatives of general formula I,in which V, W, n, R, R', i, j, Y and Z have the meaning that is indicated in the description. The compounds according to the invention are distinguished by a diazacycloalkane substituent. They have at their disposal a special action with respect to the action that destabilizes the androgen receptor and can be used, for example, for treating prostrate cancer.

Piperazine derivatives that destabilize androgen receptors

Growing community of inventors

Berlin, Germany

Andreas Reichel